Duopharma Biotech Bhd posted a 32.2% year-on-year increase in profit after tax (PAT) to RM60.59 million for the first half ended June 30, 2026 (1H26), driven by a more favourable product mix, a stronger ringgit that lowered input costs for most active pharmaceutical ingredients and continued operational efficiencies.
The stronger earnings came despite cumulative revenue edging 0.5% lower to RM482.24 million from RM484.52 million a year earlier, mainly due to the normalisation of insulin sales to the public sector following a one-off surge last year.
Excluding insulin sales, Duopharma Biotech recorded underlying revenue growth, supported by expansion in private market segments, exports and stronger contributions from its Consumer Healthcare business.
Second-quarter revenue stood at RM234.36 million, down 5.5% from the preceding quarter, in line with the group’s historical sales pattern as public-sector demand normalised alongside the Health Ministry’s annual procurement cycle.
Group Chief Executive Officer Wan Amir-Jeffery Wan Abdul Majid said the performance was supported by a healthy order book, diversified revenue streams and participation across both public and private healthcare markets.
The group will continue focusing on operational excellence, cost management and supply-chain resilience amid geopolitical and global trade uncertainties.
The board maintained an interim dividend of 1.5 sen per share, amounting to approximately RM14.43 million, with payment scheduled for Sept 21, 2026.
